Likewise, randomized controlled trials and real-world studies showed that the PASI90 response of anti-IL23 agents was higher than that of both anti-TNF and anti-IL12/23 classes.37, 38, 39, 40, 41, 42 The overall efficacy of anti-IL23 and anti-IL17 agents in patients with psoriasis in this study was found to be similar, and the literature presents varying results regarding the comparison of the efficacy and safety of these agents. This evidence concerns the gene IL17A and psoriasis.